Editing Bipolar I disorder (section)

===Medication===
[[Mood stabilizer]]s are often used as part of the treatment process.<ref>{{Cite news|url=https://health.usnews.com/health-care/for-better/articles/2017-07-20/can-people-recover-from-bipolar-disorder|title=Can People Recover From Bipolar Disorder?|last=Schwartz|first=Jeremy|date=2017-07-20|work=U.S. News & World Report}}</ref>
# [[Lithium (medication)|Lithium]] is the mainstay in the management of bipolar disorder but it has a narrow [[therapeutic range]] and typically requires monitoring<ref>{{Cite journal|url=http://www.cochrane.org/CD003013/DEPRESSN_lithium-for-maintenance-treatment-of-mood-disorders|title=Lithium for maintenance treatment of mood disorders {{!}} Cochrane|journal=Cochrane Database of Systematic Reviews|doi=10.1002/14651858.CD003013|year=2001|last1=Burgess|first1=Sally SA|last2=Geddes|first2=John|last3=Hawton|first3=Keith KE|last4=Taylor|first4=Matthew J.|last5=Townsend|first5=Ellen|last6=Jamison|first6=K.|last7=Goodwin|first7=Guy|volume=2001|issue=3|pages=CD003013|pmc=7005360}}</ref>
# [[Anticonvulsant]]s, such as [[valproate]],<ref>{{Cite journal|url=http://www.cochrane.org/CD004052/DEPRESSN_valproate-for-acutre-mood-episodes-in-bipolar-disorder|title=Valproate for acutre mood episodes in bipolar disorder {{!}} Cochrane|journal=Cochrane Database of Systematic Reviews|issue=1|pages=CD004052|doi=10.1002/14651858.CD004052|pmid=12535506|year=2003|last1=MacRitchie|first1=Karine|last2=Geddes|first2=John|last3=Scott|first3=Jan|last4=Haslam|first4=D. R.|last5=Silva De Lima|first5=Mauricio|last6=Goodwin|first6=Guy}}</ref> [[carbamazepine]], or [[lamotrigine]]
# [[Atypical antipsychotic]]s, such as [[quetiapine]],<ref>{{cite journal|last1=Datto|first1=Catherine|title=Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression |journal=Annals of General Psychiatry|date=11 March 2016|volume=15|pages=9 |doi=10.1186/s12991-016-0096-0 |pmid=26973704 |pmc=4788818 |doi-access=free }}</ref><ref>{{cite journal |last1=Young |first1=Allan |title=A Randomised, Placebo-Controlled 52-Week Trial of Continued Quetiapine Treatment in Recently Depressed Patients With Bipolar I And Bipolar II Disorder|journal=World Journal of Biological Psychiatry |date=February 2014 |volume=15|issue=2|pages=96–112 |doi=10.3109/15622975.2012.665177 |pmid=22404704|s2cid=2224996 }}</ref> [[risperidone]], [[olanzapine]], or [[aripiprazole]]
# [[Electroconvulsive therapy]], a psychiatric treatment in which [[seizure]]s are [[electrically]] induced in [[general anaesthesia|anesthetized]] patients for [[therapeutic effect]]

[[Antidepressant]]-induced mania occurs in 20–40% of people with bipolar disorder. Mood stabilizers, especially lithium, may protect against this effect, but some research contradicts this.<ref>{{Cite journal|last1=Goldberg|first1=Joseph F|last2=Truman|first2=Christine J|date=2003-12-01|title=Antidepressant-induced mania: an overview of current controversies|journal=Bipolar Disorders|volume=5|issue=6|pages=407–420|doi=10.1046/j.1399-5618.2003.00067.x|pmid=14636364|issn=1399-5618}}</ref>

A frequent problem in these individuals is non-adherence to pharmacological treatment; long-acting injectable antipsychotics may contribute to solving this issue in some patients.<ref>{{Cite journal|last1=Tohen|first1=Mauricio|last2=Goldberg|first2=Joseph F.|last3=Hassoun|first3=Youssef|last4=Sureddi|first4=Suresh|date=2020-06-16|title=Identifying Profiles of Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic|journal=The Journal of Clinical Psychiatry|volume=81|issue=4|doi=10.4088/JCP.OT19046AH1|issn=1555-2101|pmid=32558403|s2cid=219923839|doi-access=free}}</ref>

A review of validated treatment guidelines for bipolar disorder by international bodies was published in 2020.<ref>{{Cite journal|last1=Verdolini|first1=Norma|last2=Hidalgo-Mazzei|first2=Diego|last3=Del Matto|first3=Laura|last4=Muscas|first4=Michele|last5=Pacchiarotti|first5=Isabella|last6=Murru|first6=Andrea|last7=Samalin|first7=Ludovic|last8=Aedo|first8=Alberto|last9=Tohen|first9=Mauricio|last10=Grunze|first10=Heinz|last11=Young|first11=Allan H.|date=2020-12-22|title=Long-term treatment of bipolar disorder type I: A systematic and critical review of clinical guidelines with derived practice algorithms|url=https://pubmed.ncbi.nlm.nih.gov/33354842|journal=Bipolar Disorders|volume=23|issue=4|pages=324–340|doi=10.1111/bdi.13040|issn=1399-5618|pmid=33354842|s2cid=229693238}}</ref>